About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both pharmaceutical manufacturers and healthcare providers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $70 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 10,000 people. AmerisourceBergen is ranked #26 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
This news release contains forward-looking statements about
AmerisourceBergen's future business and financial performance, estimates
and prospects. These statements are based on management's current
expectations and are subject to uncertainty and change in circumstances.
Among the factors that could cause actual results to differ materially
from those projected, anticipated or implied are the following: changes
in pharmaceutical market growth rates; the loss of one or more key
customer or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other dispute with customers or suppliers; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; changes in U.S. legislation or regulatory action affecting
pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare; changes in regulatory or clinical medical
guidelines and/or labeling for the pharmaceuticals we distribute,
including erythropoiesis-stimulating agents (ESAs) used to treat anemia
patients; price inflation in branded pharmaceuticals and price deflation
in generics; significant breakdown or interruption of our information
technology systems; our inability to implement an enterprise resource
planning (ERP) system to handle business and financial processes within
AmerisourceBergen Drug Corporation's operations and our corporate
functions without operating problems and/or cost overruns; success of
integration, restructuring or systems initiatives; interest rate and
foreign currency exchange rate fluctuations; economic, business,
competitive and/or regulatory developments in Canada, the United Kingdom
and elsewhere outside of the United States; the impact of divestitures
or the acquisition of businesses that do not perform as we expect or
that are difficult for us to integrate or control; our inability to
successfully complete any other transaction that we may wish to pursue
from time to time; changes in tax legislation or adverse resolution of
challenges to our tax positions; increased costs of maintaining or
reducing our ability to maintain adequate liquidity and financing
sources; continued volatility and further deterioration of the capital
and credit markets; and other economic, business, competitive, legal,
tax, regulatory and/or operational factors affecting our business
generally. Our most recent annual report on Form 10-K, quarterly reports
on Forms 10-Q and current reports 8-K (which we may revise or supplement
in future reports filed to the SEC) provide additional information about
these risks, uncertainties and other matters. We do not undertake to
update our forward-looking statements.
SOURCE: AmerisourceBergen Corporation
AmerisourceBergen
Michael N. Kilpatric, 610-727-7118
mkilpatric@amerisourcebergen.com